On Wednesday, Citi downgraded shares of Illumina (NASDAQ:ILMN) from Buy to Neutral, also reducing the price target to $165 from $190. According to InvestingPro data, analyst targets for Illumina currently range from $120 to $252, with 13 analysts recently revising their earnings expectations downward. The stock, which has seen a 35.7% surge over the past six months, currently trades at $147.53.
The adjustment comes after the firm's analysis indicated that while Illumina has begun to identify and execute cost initiatives, these efforts are now adequately reflected in the stock's valuation, trading at approximately 19 times forward two years' enterprise value to EBITDA (FY2 EV/EBITDA).
The analyst noted that Illumina's next phase of growth is contingent on its top-line performance, which currently faces uncertainty.
Factors such as the shift in pricing and consumables mix, along with a subdued instrument market, contribute to this outlook. InvestingPro data reveals that while the company maintains a healthy gross profit margin of 67.6%, revenue declined by 1.7% in the last twelve months, with forecasts suggesting a 4% decrease in FY2024.
While confident in the company's ability to meet its margin targets in the short and long term, the current valuation compared to peers—some of which are experiencing faster top-line growth—warrants Illumina's stock to trade in line with its peer group until it can demonstrate above-average top-line growth.
The report also highlighted potential headwinds for Illumina, including competition in China's mid-throughput market and a weaker macroeconomic environment. Additionally, a cautious stance on instrument growth for the next year, as indicated by management's reluctance to project growth in this area, was mentioned as a consideration.
Despite these concerns, the analyst's perspective remains more constructive than negative. The report acknowledges the significant efforts by Illumina's management to rebuild confidence with customers and investors amid challenging macro conditions and the impact of GRAIL on margins and earnings power. InvestingPro analysis indicates the company operates with moderate debt levels and maintains strong liquidity, with a current ratio of 2.43.
For deeper insights into Illumina's financial health and detailed valuation metrics, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers. The revised valuation reflects these factors, with the stock priced at around 19 times FY25 EV/EBITDA and 17 times FY26.
In other recent news, Illumina Inc (NASDAQ:ILMN). has announced significant advancements in its operations and financial performance. The company's third-quarter earnings and revenue met consensus estimates, with a notable upside in both margins and earnings per share (EPS). Despite a challenging macroeconomic environment, Illumina showcased optimism for a return to growth in 2025.
Analyst firms have responded to these developments with varying ratings and price target adjustments. Stephens maintained an Overweight rating, while Morgan Stanley (NYSE:MS) resumed coverage with an Equalweight rating. Baird kept a Neutral rating but increased the price target, while TD Cowen held a Buy rating.
In addition, Illumina is set to introduce the latest version of its cancer research assay, TruSight Oncology 500 v2 (TSO 500 v2), designed for comprehensive genomic profiling of tumors. The new assay promises environmental benefits with reduced packaging and fewer tubes, coupled with improved user-friendliness. Preliminary data on TSO 500 v2's analytical performance and automation compatibility will be showcased in poster presentations at the annual meeting of the Association of Molecular Pathology (AMP (OTC:AMLTF)).
Furthermore, Illumina's transition from the NovaSeq 6000 to the newer NovaSeq X model has been positively received, contributing to an increase in high-throughput consumables revenue.
The company also announced the acquisition of Fluent (NASDAQ:FLNT) BioSciences and a share repurchase, indicating a strong financial position. Despite a 2% year-over-year decrease in third-quarter revenue, Illumina raised its guidance for both operating margin and earnings per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.